Quantcast

Latest National Institute for Health and Clinical Excellence Stories

2008-08-11 18:00:58

BRITAIN'S National Health Service comes under intense scrutiny, but it remains the envy of the world. The principle of free treatment for all is one which has stood proud since the NHS was created 60 years ago. Huge strides have been made in the development of treatment since then, to the point where some patients are finding drugs which they believe may save or prolong their lives are being denied to them. Research by the Rarer Cancers Forum claims there is a postcode lottery when...

2008-08-11 18:00:58

Patients with rare cancers are being left to die due to a postcode lottery over who gets access to drugs, research out today suggests. A study from the Rarer Cancers Forum found wide variations across England in the number of patients granted access to medicines. The charity obtained full details under the Freedom of Information Act from 62 of England's 152 primary care trusts. It revealed that 100 per cent of applications from patients were rejected in some areas of the country, but in...

2008-08-11 03:00:47

COVENTRY health chiefs are supporting a draft decision to reject four new cancer drugs for patients with advanced kidney cancer. The National Institute for Health and Clinical Excellence (Nice) decided that sunitinib, bevacizumab, sorafenib and Torisel are not a cost-effective use of NHS cash. For example bevacizumab costs around pounds 23,000 per patient per year. Dr Peter Barker, public health consultant at Coventry Teaching Primary Care Trust (PCT) said: "Coventry PCT is supportive...

2008-08-09 06:00:22

By Barry Nelson A CANCER patient who has survived in the past year because of a wonder drug has condemned plans to deny it to other patients because of the cost. Stan Craddock, 63, from Darlington, said he survived the past ten months because of the drug Sutent. Last night, he said he could not believe that such a powerful cancer drug was effectively going to be banned by the NHS. This followed the draft guidance from the National Institute for Health and Clinical Excellence (Nice)...

2008-08-08 00:00:39

Britain's National Health Service said it rejected four new drugs designed to treat advanced kidney cancer because the cost is too high. The National Institute for Health and Clinical Excellence said the drugs -- Sutent (sunitinib), Avastin (bevacizumab), Nexavar (sorafenib) and Torisel (temsirolimus) -- are too expensive and the money can be better put to other use, the Times of London said Thursday. The newspaper said cancer organizations are outraged by the decision. Advocates for the...

2008-08-08 00:00:11

By Ian Johnston CAMPAIGNERS EXPRESSED outrage yesterday at a decision to deny four drug treatments to NHS patients with advanced kidney cancer. The National Institute for Health and Clinical Excellence (Nice) issued draft guidance rejecting the drugs Sutent (sunitinib), Avastin (bevacizumab), Nexavar (sorafenib) and Torisel (temsirolimus). This leaves patients with only one treatment option - interferon. Professor John Wagstaff, from the South Wales Cancer Institute, said there was "no...

2008-08-08 00:00:11

By JEREMY LAURANCE The big question Why are we asking this now? CANCER CHARITIES, kidney specialists and campaigners were outraged yesterday when the National Institute for Clinical Excellence (Nice), announced that it had rejected four new drugs for advanced kidney cancer as too expensive for the NHS. In draft guidance, the medicines watchdog said that the drugs can extend life by five to six months on average but they cost too much. The money would do more good if it were spent...

2008-08-07 18:01:52

PATIENTS with advanced kidney cancer will be denied four treatments on the NHS under new guidelines. The National Institute for Health and Clinical Excellence (Nice) issued draft guidance rejecting the drugs. Charities expressed outrage at the decision. (c) 2008 Liverpool Echo. Provided by ProQuest Information and Learning. All rights Reserved.

2008-08-07 18:00:00

By JANE KIRBY PATIENTS with advanced kidney cancer will be denied four treatments on the NHS under new guidelines published yesterday. The National Institute for Health and Clinical Excellence (Nice) issued draft guidance rejecting the drugs Sutent (sunitinib), Avastin (bevacizumab), Nexavar (sorafenib) and Torisel (temsirolimus). Primary care trusts in Merseyside and Cheshire had already agreed to start offering Sutent on the NHS, as reported by the Daily Post in December last year....

2008-08-07 18:00:00

By Greg Tindle A WELSH cancer expert has described as "an outrage" plans to deny patients with advanced kidney cancer four types of drug treatment on the NHS. Under new guidelines the National Institute for Health and Clinical Excellence (Nice) - the Government's medicines watchdog - has turned down the use of the drugs saying they are not cost effective. Charities have expressed concern at the decision, saying it has left patients only one treatment option - interferon - to which...


Word of the Day
bellycheer
  • Good cheer; viands.
  • To revel; to feast.
The word 'bellycheer' may come from 'belle cheer', "good cheer".
Related